At a glance
ClinicalIndex Comparison RecordN/ACompleted· 162 enrolled
Drug / intervention
Paclitaxeldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Predicting the Efficacy of Paclitaxel Plus Ramucirumab in Advanced Gastric Cancer.
In Brief
An observational study evaluating Paclitaxel for Gastric Cancer and 3 related conditions. Completed, enrolled 162 participants across 2 sites in 2 countries.
Detailed Summary
With advances in chemotherapy for gastric cancer, it is important to identify patients who will respond effectively to specific therapies. This longitudinal study aimed to establish a liquid-biopsy assay that can predict response to ramucirumab plus paclitaxel therapy in patients with advanced gastric cancer.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Cancer, Chemotherapy Effect, Paclitaxel, Ramucirumab
CountriesJapan, United States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartOct 2018
First PostedJul 2024
Primary CompletionFeb 2025
Study CompletionJul 2025
TodayJul 2026
First PostedJul 8, 2024
Enrollment StartOct 1, 2018
Primary CompletionFeb 18, 2025
Study CompletionJul 1, 2025
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 2.0 years ago
Interventions
Paclitaxeldrug
Gastric cancer second-line Chemotherapy (paclitaxel plus ramucirumab)